Back to Results
First PageMeta Content
Pharmacology / Medicine / Natalizumab / Alemtuzumab / Fingolimod / Clinical trial / Immunosuppressants / Immunology / Multiple sclerosis


7.10 ALEMTUZUMAB solution for infusion, 10 mg/ mL; Lemtrada®; Genzyme (Sanofi-Aventis Australia Pty Ltd). Purpose of Application
Add to Reading List

Document Date: 2015-03-16 01:05:14

Open Document

File Size: 54,02 KB

Share Result on Facebook
UPDATE